A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
for SLE
10 locations incl. Avondale
Sponsor: Cullinan Therapeutics Inc.
Sex: All·Age: 18 - 70
Code: NCT06613360·Phase 1·Recruiting·Listed Sep 2024